CN107058556A - It is a kind of to be used to assess the method that 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotees cancer risk - Google Patents
It is a kind of to be used to assess the method that 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotees cancer risk Download PDFInfo
- Publication number
- CN107058556A CN107058556A CN201710322541.XA CN201710322541A CN107058556A CN 107058556 A CN107058556 A CN 107058556A CN 201710322541 A CN201710322541 A CN 201710322541A CN 107058556 A CN107058556 A CN 107058556A
- Authority
- CN
- China
- Prior art keywords
- methano
- hexahydro
- prl
- cancer
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
Abstract
It is used to assess the method that 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotees cancer risk the invention provides a kind of, the step of this method includes biomarker expression in detection biological sample, the biomarker is PRL 3.The method of the present invention is easy, and correlation is higher, can be with the rush cancer risk of rapid evaluation 5a,6,9,9a-hexahydro-6,9-methano-2,4.It is the 5a,6,9,9a-hexahydro-6,9-methano-2,4 key gene related to prostate cancer that the present invention filters out PRL 3 by bioinformatic analysis, confirm that 5a,6,9,9a-hexahydro-6,9-methano-2,4 can be by promoting PRL 3 to express in terms of cytology, the migration migration ability of prostate gland cancer cell is improved, points out 5a,6,9,9a-hexahydro-6,9-methano-2,4 that there is the risk for promoting prostate cancer development.The present invention causes the key gene of human diseases to provide important reference value to find environmental contaminants, and the targeted therapy of the human diseases for future caused by environmental contaminants provides important clue.
Description
Technical field
The invention belongs to biological technical field, it is related to a kind of method for promoting cancer risk for environmental contaminants, especially relates to
And a kind of 5a,6,9,9a-hexahydro-6,9-methano-2,4 of assessing exposes the method for causing prostate cancer.
Background technology
Just constantly entering the life of people with the progress, the raising of industrialized level, all kinds of chemicals of science and technology
Living, wherein persistence Environmental pollutant (POPs) can not be ignored to the harm of environment and the influence of health, bag
Include two uh English (PCDD/Fs), polycyclic aromatic hydrocarbon (PAHs), Polychlorinated biphenyls (PCBs), organic chlorine pesticide benzoepin etc..
5a,6,9,9a-hexahydro-6,9-methano-2,4 is a kind of organo-chlorine pesticide, is widely used in as insecticide in agricultural production, with high bio-toxicity, potential
Carcinogenicity and environmental estrogens effect the features such as, its pollution to environment and biological toxic action was caused in recent years
Extensive concern.As a kind of persistence organic pollutant, the relation research on 5a,6,9,9a-hexahydro-6,9-methano-2,4 and human diseases at present is only limitted to stream
Row disease learns investigation, lacks the analysis of the data and bioinformatics in laboratory, the relation of 5a,6,9,9a-hexahydro-6,9-methano-2,4 and cancer how, the key that is related to
The factor and molecular mechanism are not yet illustrated completely so far.
The generation development that environmental contaminants are exposed with a variety of diseases of the mankind especially cancer is closely related, for research environment
The toxicity feature and the relation of gene alteration of pollutant, disclose the molecular mechanism of toxic action, and biochip technology is good with its
Detection basis and analytical standard applied to environmental contaminants disease mechanisms analyze and research.By to gene expression profile number
According to being analyzed, the situation of different tissues or different time gene expression difference can be disclosed, is conducive to the molecular mechanism of disease
Analysis, diagnosis, prognosis and risk assessment.
Biochip technology is used to analysis pollutant in field of environmental toxicology and causes damage to some tissues or organ
Molecular mechanism, prediction and the health risk for assessing human diseases, but how to screen pathogenic key gene, determine the gene expression
The relation changed with disease there is no effectively reliable method.
NextBio and Metacore softwares can be achieved on two softwares of human diseases prediction and genetic analysis, at present
It has been be widely used that, two kinds of databases can excavate the key message in gene expression profile, but the two but has each
Advantage and disadvantage.Research in NextBio databases is generally the research on clinical medicine, its result and the more phase of situation clinically
Closely, but limited by research number so that the accuracy for analyzing result is affected.Metacore databases have compared with
Many functional analyses, result reliability and the degree of accuracy are high, are good at analysis transcription factor regulation and control net, but can only realize people, rat,
The gene microarray analysis of these three species of mouse.
The content of the invention
In view of the deficiencies in the prior art that the above-mentioned bio-toxicity as persistence organic pollutant 5a,6,9,9a-hexahydro-6,9-methano-2,4 is detected, the present invention
A kind of method for promoting cancer risk for Evaluation Environment pollutant 5a,6,9,9a-hexahydro-6,9-methano-2,4 is provided, is provided in particular in detecting the biology that 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotees cancer risk
Mark.Cell migration is promoted to prostate gland cancer cell and the effect of profit is invaded present invention discover that PRL-3 can participate in 5a,6,9,9a-hexahydro-6,9-methano-2,4, is 5a,6,9,9a-hexahydro-6,9-methano-2,4
Exposure and the maximally related key gene of prostate cancer.
The present invention inquires into influence of the 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure to vascular endothelial cell gene expression profile first, is drawn using 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure
The difference expression gene risen carries out the analysis of bioinformatics, that is, utilizes Metacore software analysis transcription factor regulation and control net, profit
With the gene expression profile of the more known disease of Nextbio databases, the consistent gene of expression variation tendency is obtained.To prostate
Find there are 68 genes in the comparative analysis of cancer difference expression gene in the common change raised or lowered, PRL-3 expression rises
Most substantially, and regulated and controled by three kinds of transcription factors CREB1, p53, ESR1.Find that it participates in turning for a variety of cancers through literature survey
Move and be in progress, further cytologic experiment also confirms that PRL-3 can participate in 5a,6,9,9a-hexahydro-6,9-methano-2,4 and promote cell migration to prostate gland cancer cell and invade
The effect of profit.This research has filtered out the key factor PRL-3 that 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotes prostate cancer, to disclose 5a,6,9,9a-hexahydro-6,9-methano-2,4 and prostate cancer
Relation provides important experimental basis.
Technical scheme is as follows：
A kind of step for being used to assess biomarker expression in the method that 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotees cancer risk, including detection biological sample
Suddenly, the biomarker is PRL-3.
Further, in the above-mentioned technical solutions, the biomarker is one kind in PRL-3 albumen or PRL mRNA
Or two kinds.
Further, in the above-mentioned technical solutions, the overexpression of the detection based on PRL-3.Preferentially, the PRL-3
Overexpression be the overexpression of PRL-3 albumen, PRL mRNA overexpression or PRL-3 albumen and PRL mRNA overexpression.
Further, in the above-mentioned technical solutions, cell, product of cell lysis of the biological sample for culture, tissue,
Tissue Lysis product, whole blood, blood plasma, serum.Vascular endothelial cell has different physiological roles, can produce and secrete a variety of biologies
Active material, participates in the normal regulating of body, is played an important role in terms of vessel homeostasis is maintained, and the generation development with cancer is close
Cut is closed, and vascular endothelial cell can be used as currently preferred biological sample.
The present invention also provides described biomarker PRL-3 and is assessing the application during 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotees cancer risk.
Beneficial effects of the present invention：
Promote cancer there is provided detection 5a,6,9,9a-hexahydro-6,9-methano-2,4 the invention provides a kind of method for Evaluation Environment pollutant 5a,6,9,9a-hexahydro-6,9-methano-2,4 rush cancer risk
The biomarker PRL-3 of risk.The method of the present invention is easy, and correlation is higher, can be with the rush cancer risk of rapid evaluation 5a,6,9,9a-hexahydro-6,9-methano-2,4.
This research and utilization gene expression spectrum analysis relation of 5a,6,9,9a-hexahydro-6,9-methano-2,4 and disease, is filtered out using bioinformatics method
5a,6,9,9a-hexahydro-6,9-methano-2,4 promotes the key factor of prostate cancer, and tumor promotion and the PRL-3 expression rise changes of 5a,6,9,9a-hexahydro-6,9-methano-2,4 have been inquired into from gene aspect
It is relevant.Expose closely related with prostate cancer present invention firstly provides 5a,6,9,9a-hexahydro-6,9-methano-2,4, and propose 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure with prostate cancer most first
Related key gene is PRL-3.The present invention causes the key gene of human diseases to provide important to find environmental contaminants
Reference value, and the targeted therapy of the human diseases for future caused by environmental contaminants provides important clue.
Brief description of the drawings
Fig. 1 is that the human diseases related to 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure is analyzed using Metacore software predictions.
Fig. 2 is that the cancer related to 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure is analyzed using Nextbio software predictions.
Fig. 3 is the research on the gene expression profile of prostate cancer.
Fig. 4 is that 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposes the comparison changed with prostate cancer difference expression gene.
Fig. 5 is that 5a,6,9,9a-hexahydro-6,9-methano-2,4 causes PC3 cell PRL-3 expressions to raise (P*<0.05vs D).
Fig. 6 is influence (P** of the PRL-3 inhibitor interference 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure to PC3 cell migration abilities<0.01).
Fig. 7 is influence (P** of the PRL-3 inhibitor interference 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure to PC3 cell invasion abilities<0.01).
Embodiment
Following embodiment is easy to be better understood from the present invention, but does not limit the present invention.In addition, in following embodiments,
Unless otherwise specified, used experimental method is conventional method, and material therefor, reagent etc. can be from biological or chemical reagents
Company buys.
Embodiment 1
(1) 5a,6,9,9a-hexahydro-6,9-methano-2,4 causes vascular endothelial cell difference expression gene to change：
5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure processing is carried out to vascular endothelial cell (HUVEC-C), experiment is divided into two groups：DMSO control group (diformazans
Base sulfoxide, D), 5a,6,9,9a-hexahydro-6,9-methano-2,4 experimental group (endosulfan, ES).The concentration of control group DMSO 0.1%, 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure concentrations are 20 μM,
Open-assembly time is 48 hours, collects cell extraction total serum IgE and carries out genetic chip [Agilent Human Gene Expression
Profiling, upper Haikang into biological Co., Ltd, Whole Human Genome Oligo Microarray (4x44K,
Agilent Technologies)] analysis, have 457 relative to control group when being exposed by gene expression spectrum analysis discovery 5a,6,9,9a-hexahydro-6,9-methano-2,4
Individual down regulation of gene expression and 319 gene expressions up-regulation.
(2) 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure causes the forecast analysis of human diseases：
For the down-regulated gene and up-regulated gene filtered out in above-mentioned (1), Metacore software predictions and 5a,6,9,9a-hexahydro-6,9-methano-2,4 phase are utilized
The top ten human diseases of pass, its correlation presses-log10(P-Value) value arrangements, numerical value is more big then to be represented and the disease
Correlation is higher.As a result such as Fig. 1, Fig. 1 shows, is disease in the male sexual system with the maximally related disease of 5a,6,9,9a-hexahydro-6,9-methano-2,4, prostate cancer, preceding
Row gland disease etc..
It is related to 5a,6,9,9a-hexahydro-6,9-methano-2,4 by NextBio software predictions for the down-regulated gene and up-regulated gene filtered out in above-mentioned (1)
Human cancer, sorted according to the height of scoring, the degree of relevancy that the fraction representation disease of scoring exposes with 5a,6,9,9a-hexahydro-6,9-methano-2,4.As a result such as
Fig. 2, Fig. 2 show, the top ten cancer related to 5a,6,9,9a-hexahydro-6,9-methano-2,4, including stomach cancer, liver cancer, the cancer of the brain, intestinal cancer, prostate cancer etc..
By Metacore and Nextbio software analysis results, determine that 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure is closely related with prostate cancer.
Embodiment 2
(1) gene expression spectrum analysis of human prostate cancer：
In order to study the correlation between 5a,6,9,9a-hexahydro-6,9-methano-2,4 and prostate cancer, in NextBio databases according to the behaviour of research species, number
One is selected on prostatitis for the standard screen that data, the common differential gene correlation P values of genetic chip are less than 0.05 according to type
The clinical data of gland cancer gene expression profile (comes from Stanford Microarray Database, GSE3933；URLhttp://genome-www5.stanford.edu/stanfordUniversity, document sectional drawing such as Fig. 3).The data are by this
Tan Fu universities database is provided, and is to contain 62 prostate cancer tissues, 41 normal prostata tissues and 9 lymphs to carry down
The gene expression profile of cancer is moved, about 26,000 gene, wherein prostate cancer tissue and normal prostatic have been detected in whole research
Tissue, which is compared, has 7767 genes to occur differential expressions change.
(2) comparative analysis that difference expression gene caused by 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure changes with prostate cancer difference expression gene：
The gene expression profile (Bs1) and the base of prostate cancer for the 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure for being obtained embodiment 1 using NextBio softwares
Because express spectra (Bs2) is compared analysis, as a result such as Fig. 4, finding the gene of common differential expression has 142, becomes with identical
The gene of change trend has 68, wherein 18 gene co expression up-regulations, 50 gene co expressions are lowered.Wherein PTP4A3 bases
Because change multiple is maximum, the albumen of PTP4A3 codings is referred to as PRL-3.
(3) the transcription factor regulation and control net analysis of 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure：
68 common differential genes with Similar trend that screening is obtained in step (2) are uploaded to Metacore
Database, carries out transcription factor regulation and control net analysis.30 related transcription factor regulated and control networks, wherein TOP V are obtained most
Related transcription factor, its order is according to P-Value big minispread, and as shown in table 1,5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure is related to prostate cancer
Transcription factor is respectively CREB1, p53, SP1, c-Myc, ESR1.By comparing five transcription factor regulated and control networks, find
PTP4A3 is in three transcription factor regulated and control networks, by CREB1, p53, ESR1 direct regulation and control.
The 5a,6,9,9a-hexahydro-6,9-methano-2,4 of table 1. exposes and maximally related five transcription factors of prostate cancer
Embodiment 3
5a,6,9,9a-hexahydro-6,9-methano-2,4 exposes the change for causing PRL-3 expressions：
5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure processing is carried out to prostate cancer PC3 cells, experiment is divided into two groups：DMSO control groups (dimethyl sulfoxide (DMSO),
D), 5a,6,9,9a-hexahydro-6,9-methano-2,4 experimental group (endosulfan, ES).The concentration of control group DMSO 0.1%, 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure concentrations are 20 μM, open-assembly time
For 48 hours, the cell of DMSO groups and 5a,6,9,9a-hexahydro-6,9-methano-2,4 experimental group is collected, total serum IgE is extracted with Trizol methods, RNA concentration is determined and carries out
RNA quality inspections.QRT-PCR reactions are carried out using SYBR green (Applied Biosystems, ABI) method, primer is designed
(2) PRL-3 and GAPDH, be shown in Table, using GAPDH as internal reference, with 2-ΔΔCtMethod is relative by handling sample by mRNA differential expressions
Represented in the multiple of untreated sample.As a result as shown in figure 5,5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure (20 μM) can cause PRL-3mRNA expression to rise
Height, with statistical significance.
The primer sequence of table 2. and relevant information
Embodiment 4
PRL-3 interference 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposures cause the migration of PC3 cells and invade the change of profit ability：
5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure processing is carried out to prostate cancer PC3 cells, experiment is divided into four groups：Normal group (C), DMSO controls
Group (D), 5a,6,9,9a-hexahydro-6,9-methano-2,4 experimental group (20 μM of ES), 5a,6,9,9a-hexahydro-6,9-methano-2,4 adds PRL-3 inhibitor group (20 μM of ES+PRL-3 inhibitor), PRL-3
Inhibitor concentration is 10 μM, and open-assembly time is 48 hours, determines the migration of each group cell and invades the change of profit ability.
In order to determine cell migration transfer ability, prepare 100 μ L PC3 cell suspensions with the nutrient solution of serum-free and be put into
In layer cell, 500 μ L completeness culture mediums (containing 10% hyclone) are placed in bottom chamber, in 37 DEG C, 5%CO2Incubator
Middle incubation 24h, PBS, 4%PFA dabs the cell of microporous barrier upper surface with cotton swab after fixing, dye drying, remove micro-
Pore membrane, which is placed on slide, carries out Microscopic observation, with have migration ability migrate into lower floor cells on total cells number percentage
Represent (Fig. 6).Cell invasion ability determines the Matrigel (BD Biosciences) in advance configuring serum free medium and added
Enter in the cell of upper strata, cover cell microporous barrier, other are identical with migration experiment, result, cell invasion ability are observed after culture 48h
To there is the percentage for invading the cells on total cells number that profit ability enters lower floor to represent (Fig. 7).
As a result show, 5a,6,9,9a-hexahydro-6,9-methano-2,4 exposure can promote the migration of PC3 cells and invade profit ability, and press down after the processing of PRL-3 inhibitor
Make the rush PC3 migration of 5a,6,9,9a-hexahydro-6,9-methano-2,4 and invaded profit effect, point out PRL-3 to take part in the tumor promotion of 5a,6,9,9a-hexahydro-6,9-methano-2,4 as key factor.
To sum up, it is the 5a,6,9,9a-hexahydro-6,9-methano-2,4 crucial base related to prostate cancer that the present invention filters out PRL-3 by bioinformatic analysis
Cause, confirms that 5a,6,9,9a-hexahydro-6,9-methano-2,4 can improve the migration migration ability of prostate gland cancer cell by promoting PRL-3 to express in terms of cytology,
Point out 5a,6,9,9a-hexahydro-6,9-methano-2,4 that there is the risk for promoting prostate cancer development.These analyses and experimental result are that 5a,6,9,9a-hexahydro-6,9-methano-2,4 rush cancer is made for determination PRL-3
Key factor provides important reference frame.
Claims (6)
1. a kind of method for being used to assess 5a,6,9,9a-hexahydro-6,9-methano-2,4 rush cancer risk, including in detection biological sample the step of biomarker expression,
Characterized in that, the biomarker is PRL-3.
2. according to the method described in claim 1, it is characterised in that the biomarker is PRL-3 albumen or PRL mRNA
One or both of.
3. according to the method described in claim 1, it is characterised in that the overexpression of the detection based on PRL-3.
4. method according to claim 3, it is characterised in that the overexpression of the PRL-3 is PRL-3 albumen or PRL
One or both of mRNA overexpression.
5. according to the method described in claim 1, it is characterised in that the biological sample cracks production for cell, the cell of culture
Thing, tissue, Tissue Lysis product, whole blood, blood plasma, serum.
6. biomarker PRL-3 as claimed in claim 1 is assessing the application during 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotees cancer risk.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710322541.XA CN107058556A (en) | 2017-05-09 | 2017-05-09 | It is a kind of to be used to assess the method that 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotees cancer risk |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710322541.XA CN107058556A (en) | 2017-05-09 | 2017-05-09 | It is a kind of to be used to assess the method that 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotees cancer risk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107058556A true CN107058556A (en) | 2017-08-18 |
Family
ID=59597539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710322541.XA Pending CN107058556A (en) | 2017-05-09 | 2017-05-09 | It is a kind of to be used to assess the method that 5a,6,9,9a-hexahydro-6,9-methano-2,4 promotees cancer risk |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107058556A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040010045A1 (en) * | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| WO2016024918A1 (en) * | 2014-08-13 | 2016-02-18 | Agency For Science, Technology And Research | Diagnosis of cancer |
-
2017
- 2017-05-09 CN CN201710322541.XA patent/CN107058556A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040010045A1 (en) * | 2001-09-07 | 2004-01-15 | Taolin Yi | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer |
| WO2016024918A1 (en) * | 2014-08-13 | 2016-02-18 | Agency For Science, Technology And Research | Diagnosis of cancer |
Non-Patent Citations (4)
| Title |
|---|
| ELISABETH FEIK等: ""Integrative Analysis of Prostate Cancer Aggressiveness"", 《THE PROSTATE》 * |
| ESTEN N. VANDSEMB等: ""Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration"", 《J TRANSL MED》 * |
| PIERRE R. BAND等: ""Prostate Cancer Risk and Exposure to Pesticides in British Columbia Farmers"", 《THE PROSTATE》 * |
| 林丽梅: ""硫丹暴露HUVEC-C细胞的基因表达谱和疾病预测分析"", 《中国学位论文全文数据库》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hause et al. | Classification and characterization of microsatellite instability across 18 cancer types | |
| Gudmundsson et al. | Discovery of common variants associated with low TSH levels and thyroid cancer risk | |
| Roderburg et al. | Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis | |
| Dyrskjøt et al. | Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification | |
| Choo et al. | Biomarkers for basal-like breast cancer | |
| Yang et al. | Genetic variations in miR-27a gene decrease mature miR-27a level and reduce gastric cancer susceptibility | |
| Lee et al. | Comparative and integrative functional genomics of HCC | |
| Fare et al. | Effects of atmospheric ozone on microarray data quality | |
| Wang et al. | Differential expression analysis of mi RNA in peripheral blood mononuclear cells of patients with non‐segmental vitiligo | |
| Voellenkle et al. | Dysregulation of circular RNAs in myotonic dystrophy type 1 | |
| Ma et al. | Transcriptome analysis revealed key prognostic genes and microRNAs in hepatocellular carcinoma | |
| CN109563544A (en) | The diagnostic assay of urine monitoring for bladder cancer | |
| Brown et al. | Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines | |
| Azzollini et al. | Constitutive BRCA1 promoter hypermethylation can be a predisposing event in isolated early-onset breast cancer | |
| Datta et al. | Chronic exposure to chewing tobacco induces metabolic reprogramming and cancer stem cell-like properties in esophageal epithelial cells | |
| Schadt | Exploiting naturally occurring DNA variation and molecular profiling data to dissect disease and drug response traits | |
| Faldoni et al. | Inflammatory breast cancer: clinical implications of genomic alterations and mutational profiling | |
| Wang et al. | Identification of proteins implicated in the development of pancreatic cancer-associated diabetes mellitus by iTRAQ-based quantitative proteomics | |
| LIN et al. | Increased oxidative damage with altered antioxidative status in type 2 diabetic patients harboring the 16189 T to C variant of mitochondrial DNA | |
| CN115927567A (en) | Personalized customized molecular residual disease detection method | |
| Izzotti et al. | Relationship between the miRNA profiles and oncogene mutations in non-smoker lung cancer. Relevance for lung cancer personalized screenings and treatments | |
| Liang et al. | Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma | |
| Brenton et al. | Molecular profiling of breast cancer: portraits but not physiognomy | |
| Tremmel et al. | Gene copy number variation analysis reveals dosage-insensitive expression of CYP2E1 | |
| Li et al. | Combined metagenomic and metabolomic analyses reveal that Bt rice planting alters soil CN metabolism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170818 |
|
| RJ01 | Rejection of invention patent application after publication |